Bioactivity:

Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabet

CAS nr:

475479-34-6

Purity:

98%

Molecular Weight:

437,51

SMILES:

CC1=C(CCOC2=CC=C(C[C@@H](C(O)=O)OC)C3=C2C=CS3)N=C(C4=CC=CC=C4)O1

Formula:

C24H23NO5S

Pathway:

Metabolism,DNA Damage/DNA Repair

Target:

PPAR,PPAR